semaglutide heart failure trial cardiovascular outcomes Beyond obesity: Novo's SELECT re-defines risk management A Skeptical Take of Semaglutide – retatrutide hfpef trial Semaglutide versus

This compares with only about 1,000 prescriptions filled for the traditional pen injection formulation of Wegovy

It is NOT a stimulant

The difference becomes more pronounced with higher-dose injectable semaglutide: Wegovy (2.4 mg weekly) demonstrated mean weight loss of approximately 15% of body weight in the STEP clinical trial program for obesity management, substantially exceeding outcomes typically seen with oral semaglutide at diabetes-approved doses

Foods high in protein, fiber, and healthy fats can naturally support GLP-1 but putting that into practice consistently is where most people struggle

View trial registration at ClinicalTrials.gov

These issues are not unique to Canada